French Guiana Wellness Network: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on French Guiana Wellness Network.

Press releases published on July 1, 2026

Jul. 1, 2026

NewAmsterdam Pharma Announces Upcoming Presentations at the Alzheimer's Association International Conference (AAIC) 2026

Indeterminate GlobeNewswire

Jul. 1, 2026

Annovis Appoints Cheng Fang, Ph.D., as Chief Scientific Officer

Indeterminate GlobeNewswire

Jul. 1, 2026

Bay Hematology Oncology and American Oncology Network Welcome Dr. Bill Gai

Indeterminate GlobeNewswire

Jul. 1, 2026

Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Indeterminate GlobeNewswire

Jul. 1, 2026

BridgeBio Raises $1 Billion in Preferred Equity to Accelerate Present and Upcoming Launches

Indeterminate GlobeNewswire

Jul. 1, 2026

NorthStrive Biosciences Announces Positive Results from Phase III of AI-Driven Drug Discovery Program with Yuva Biosciences

Indeterminate GlobeNewswire

Jul. 1, 2026

Ocular Therapeutix™ to Participate in July Scientific and Investor Conferences

Indeterminate GlobeNewswire

Jul. 1, 2026

Harrow Announces Commercial Launch of BYOOVIZ® in the United States

Indeterminate GlobeNewswire

Jul. 1, 2026

Can-Fite Phase 2a Pancreatic Cancer Study with Namodenoson Achieves Primary Safety Endpoint and Demonstrates Durable Survival Outcomes in Advanced Disease

Indeterminate GlobeNewswire

Jul. 1, 2026

AI Disruption to Transform $8.5 Billion Decentralized Clinical Trials Market as Investment Activity Surges

Indeterminate GlobeNewswire

Jul. 1, 2026

Press Release: Availability of the aide-mémoire for Q2 2026 results

Indeterminate GlobeNewswire

Jul. 1, 2026

Communiqué de presse : Mise en ligne du document «Q2 2026 aide-mémoire »

Indeterminate GlobeNewswire

Jul. 1, 2026

Santhera gibt Topline-Ergebnisse der klinischen Phase-1-Studie von Catalyst Pharmaceuticals zu AGAMREE® bekannt

Indeterminate GlobeNewswire

Jul. 1, 2026

Ipsen va acquérir Memo Therapeutics AG, élargissant son portefeuille de maladies rares grâce à l’ajout d’un anticorps premier de sa classe ciblant le polyomavirus BK  

Indeterminate GlobeNewswire

Jul. 1, 2026

Cadrenal Therapeutics Announces up to $8.8 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Indeterminate GlobeNewswire